SS differs from rhabdoid tumors and other BAF47 deficient tumors, since its key mechanism is the retargeting of the oncogenic BAF complexes through the 79th C-terminal a.a. of the SSX protein. This evidence concerns the gene SSX2 and synovial sarcoma.